scholarly article | Q13442814 |
P50 | author | Walter Ricciardi | Q13494188 |
Maurizio Sanguinetti | Q38325512 | ||
Brunella Posteraro | Q41881644 | ||
Riccardo Torelli | Q56285785 | ||
Antonietta Vella | Q57097027 | ||
Elena De Carolis | Q57097045 | ||
Patrizia Posteraro | Q96101917 | ||
Flavio De Maio | Q97687814 | ||
P2093 | author name string | Alberto Ruggeri | |
P2860 | cites work | Prospective multicenter study of the epidemiology, molecular identification, and antifungal susceptibility of Candida parapsilosis, Candida orthopsilosis, and Candida metapsilosis isolated from patients with candidemia | Q34022724 |
Epidemiology, species distribution and in vitro antifungal susceptibility of fungaemia in a Spanish multicentre prospective survey. | Q34165039 | ||
The changing epidemiology of healthcare-associated candidemia over three decades | Q34266632 | ||
Candida species: current epidemiology, pathogenicity, biofilm formation, natural antifungal products and new therapeutic options. | Q34313668 | ||
Species identification and antifungal susceptibility testing of Candida bloodstream isolates from population-based surveillance studies in two U.S. cities from 2008 to 2011. | Q34372192 | ||
Candida guilliermondii and other species of candida misidentified as Candida famata: assessment by vitek 2, DNA sequencing analysis, and matrix-assisted laser desorption ionization-time of flight mass spectrometry in two global antifungal surveillan | Q34458142 | ||
MALDI-TOF mass spectrometry in the clinical mycology laboratory: identification of fungi and beyond | Q34662276 | ||
Identification of Candida nivariensis and Candida bracarensis in a large global collection of Candida glabrata isolates: comparison to the literature | Q34937478 | ||
Update on the laboratory diagnosis of invasive fungal infections | Q35010667 | ||
Comparative evaluation of three commercial identification systems using common and rare bloodstream yeast isolates | Q35140122 | ||
Evaluation of VITEK 2 and RapID yeast plus systems for yeast species identification: experience at a large clinical microbiology laboratory | Q35784345 | ||
Epidemiology and echinocandin susceptibility of Candida parapsilosis sensu lato species isolated from bloodstream infections at a Spanish university hospital. | Q36308069 | ||
Management of invasive candidiasis and candidemia in adult non-neutropenic intensive care unit patients: Part I. Epidemiology and diagnosis. | Q37313058 | ||
Epidemiology of invasive mycoses in North America | Q37678397 | ||
Epidemiology of invasive candidiasis | Q37780088 | ||
Relative frequency of albicans and the various non-albicans Candida spp among candidemia isolates from inpatients in various parts of the world: a systematic review | Q37783462 | ||
Emerging opportunistic yeast infections | Q37832837 | ||
Current issues in the clinical management of invasive candida infections--the AGIHO, DMykG, ÖGMM and PEG web-based survey and expert consensus conference 2009. | Q37873554 | ||
Uncommon yeast infections in hematological patients: from diagnosis to treatment | Q37949642 | ||
Invasive mycoses: diagnostic challenges | Q37971083 | ||
The PATH (Prospective Antifungal Therapy) Alliance® registry and invasive fungal infections: update 2012. | Q38025819 | ||
Assessment of two new molecular methods for identification of Candida parapsilosis sensu lato species | Q38285146 | ||
Candidaemia associated with decreased in vitro fluconazole susceptibility: is Candida speciation predictive of the susceptibility pattern? | Q43079484 | ||
Prevalence and antifungal susceptibility patterns of new cryptic species inside the species complexes Candida parapsilosis and Candida glabrata among blood isolates from a Spanish tertiary hospital | Q44627979 | ||
Differentiation of Candida parapsilosis, C. orthopsilosis, and C. metapsilosis by specific PCR amplification of the RPS0 intron | Q45355167 | ||
Candidaemia with uncommon Candida species: predisposing factors, outcome, antifungal susceptibility, and implications for management. | Q45926649 | ||
Epidemiology, management, and risk factors for death of invasive Candida infections in critical care: a multicenter, prospective, observational study in France (2005-2006). | Q46072663 | ||
Significance of molecular identification and antifungal susceptibility of clinically significant yeasts and moulds in a global antifungal surveillance programme. | Q51172305 | ||
P433 | issue | 11 | |
P407 | language of work or name | English | Q1860 |
P921 | main subject | species identification | Q31887332 |
P304 | page(s) | 3841-3845 | |
P577 | publication date | 2013-08-21 | |
P1433 | published in | Journal of Clinical Microbiology | Q4041880 |
P1476 | title | Comparative evaluation of BD Phoenix and vitek 2 systems for species identification of common and uncommon pathogenic yeasts | |
P478 | volume | 51 |
Q28084765 | Are the Conventional Commercial Yeast Identification Methods Still Helpful in the Era of New Clinical Microbiology Diagnostics? A Meta-Analysis of Their Accuracy |
Q40672124 | Comparative Evaluation of the BD Phoenix Yeast ID Panel and Remel RapID Yeast Plus System for Yeast Identification |
Q35163632 | Comparison and optimization of two MALDI-TOF MS platforms for the identification of medically relevant yeast species. |
Q64281790 | Comparison between MALDI-TOF MS and MicroScan in the identification of emerging and multidrug resistant yeasts in a fourth-level hospital in Bogotá, Colombia |
Q34351558 | Comparison of the accuracy of two conventional phenotypic methods and two MALDI-TOF MS systems with that of DNA sequencing analysis for correctly identifying clinically encountered yeasts |
Q35839167 | Misidentification of a Rare Species, Cryptococcus laurentii, by Commonly Used Commercial Biochemical Methods and Matrix-Assisted Laser Desorption Ionization-Time of Flight Mass Spectrometry Systems: Challenges for Clinical Mycology Laboratories |